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Abstract 
 
Breast cancer is the most frequently diagnosed cancer among women in the United States 
and MDD is the most common mental health problem in women with breast cancer. There is 
lack of research on measures of depression in this population. This study examined the 
psychometric properties of three commonly used depression measures, the BDI-II, CES-D, and 
HRSD, with clinically depressed breast cancer patients (n = 127). Findings revealed the 
measures displayed good distributional characteristics, internal consistency, and convergent 
validity. Discriminative validity with the BAI was not demonstrated, however, and confirmatory 
factor analyses indicated that the existing models of these measures are inadequate. The results 
indicate that these measures are appropriate for use with clinically depressed breast cancer 
patients, but that further investigation of discriminative validity is necessary to better determine 
construct validity with anxiety measures. Because of inadequate fit of this sample with existing 
models, interpretation of scores on these measures may be better accomplished via reference to 
more valid structural models obtained through exploratory factor analyses, providing a more 
accurate conceptualization of the dimensions of MDD in breast cancer patients. 
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Chapter 1 
Introduction 
Breast cancer is the most frequently diagnosed cancer among women in the United States 
and second to only lung and bronchial cancer in mortality rates (Center for Disease Control and 
Prevention: National Program of Cancer Registries, 2014). Functional difficulties during and 
following treatment can include neurological impairment in the form of executive functioning, 
attention, and memory deficits (Kessler, Kent, & O’Hara, 2011; McDonald, Conroy, Ahles, 
West, & Saykin, 2012), poorer quality of life, decreased vitality, and social impairment (Hopko 
et al., 2008), physical inactivity increasing risk for cardiovascular disease (Elme et al., 2013), 
increased bodily pain and muscle rigidity (Hopko et al., 2008; Siegal et al., 2012), as well as 
fatigue, insomnia, depression, and anxiety (Kim et al., 2008; Hall, Mishel, & Germino, 2014). 
Indeed, women diagnosed with breast cancer are particularly vulnerable to depression and 
anxiety in the first year following diagnosis (Burgess et al., 2005; Hopwood, Sumo, Mills, 
Haviland, & Bliss, 2010; Reyes-Gibby, Anderson, Morrow, Shete, & Hassan, 2012). Relative to 
non-depressed patients, depressed breast cancer patients have increased functional impairment in 
terms of decreased quality of life, increased anxiety and substance use, impaired sexual 
functioning, sleep disorders, decreased immune system functioning, more rapid progression of 
cancer, more pain and fatigue, and possibly increased mortality (Deshields, Tibbs, Fan, & 
Taylor, 2006; Hopko, McIndoo, Gawrysiak, & Grassetti, 2014; Reich, Lesur, & Perdrizet-
Chevallier, 2008; Somerset, Stout, Miller, & Musselman, 2004; Spiegel & Giese-Davis, 2003). 
A recent meta-analysis indicated depression is fairly common in cancer patients, with 
prevalence ranging from 8-24% based on differential methods of assessment, type of cancer, and 
phase of cancer treatment (Krebber et al., 2014). Specific to breast cancer, major depressive 
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disorder (MDD) is the most common mental health problem, with a prevalence rate of 15-25% 
(Fann et al., 2008; Hopko et al., 2014; Massie, 2004), with some suggesting up to 50% of women 
with breast cancer experience debilitating depression (Hong, Tian, & Wu, 2014; Sachs et al., 
1995). Determining the precise prevalence and incidence of MDD in breast cancer patients has 
proven challenging due to heterogeneity among patients, overlap of depressive and medical 
symptoms, differing operational definitions and methods of assessing depression, and small, non-
representative samples in several studies. Perhaps most problematically, the psychometric 
properties of self-report and clinician-rated depression measures are highly understudied among 
breast cancer patients with well-diagnosed MDD as assessed via structured diagnostic interviews 
(Fann et al., 2008; Hopko et al., 2014). Accordingly, the primary aim of this study was to 
examine the psychometric properties of three commonly used measures of depression in breast 
cancer patients with MDD: the Beck Depression Inventory (BDI-II; Beck et al., 1996), Center 
for Epidemiologic Studies Depression Scale (CES-D; Radloff, 1977), and Hamilton Rating Scale 
for Depression (HRSD; Hamilton, 1960).    
 The psychometric properties of the BDI-II have been studied extensively among various 
samples of younger and older adults, adolescents, college students, primary care patients, and 
psychiatric outpatients (Arnau, Meagher, Norris, & Bramson, 2001; Beck et al., 1996; Dozois, 
Dobson, & Ahnberg, 1998; Huang & Chen, 2014; Osman et al., 1997; Segal, Coolidge, Cahill, & 
O’Riley, 2008; Steer, Ball, Ranieri, & Beck, 1999; Steer & Clark, 1997; Steer, Kumar, Ranieri, 
&Beck, 1998). The BDI-II is considered a highly valid and reliable measure of depression 
(Huang & Chen, 2014; Nezu et al., 2001) and with few exceptions (Seignourel, Green, & 
Schmitz, 2008; Vanheule, Desmet, Groenvynck, Rosseel, & Fontaine, 2008; Whisman, Judd, 
Whiteford, & Gelhorn, 2013) consistently yields a two factor solution: somatic-affective and 
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cognitive (Arnau et al., 2001, Huang & Chen, 2014; Steer et al., 1998). The CES-D is also well 
studied among adults, adolescents, college students, and primary care patients, (Devins et al., 
1988; Hann, Winter, Jacobsen, 1999; Knight, Williams, McGee, Olaman, 1997; Verhoeven, 
Sawyer, & Spence, 2013). The CES-D has good reliability and construct validity and although 
alternative factor structures have been reported (Carleton et al., 2013), a four-factor model 
consistently has been identified: depressive affect, absence of positive affect or anhedonia, 
somatic symptoms, and interpersonal problems and challenges (Shafer, 2006). The HRSD is 
commonly used to assess depression (Nezu et al., 2001; Steer, Beck, Riskind, & Brown, 1987) 
and a recent meta-analysis on its psychometric properties revealed the HRSD generally has good 
internal consistency, inter-rater, and test-retest reliability (Trajković et al., 2011). Although both 
two- (depression, neurovegetative: Bech, Fava, Trivedi, Wisniewski, & Rush, 2011) and three-
factor solutions (depression severity, insomnia, psychomotor behavior) have been proposed 
(Hamilton, 1960, 1967), several studies identify a four-factor solution: depression, anxiety, 
insomnia, and somatic components (Pancheri, Picardi, Pasquini, Gaetano, & Biondi, 2002; 
Shafer, 2006). In summary, the BDI-II, CES-D, and HRSD are frequently used measures of 
depression with very good psychometric properties across multiple samples and studies. 
Assessing depression in breast cancer patients has involved utilization of several self-
report instruments. For example, the Hospital Anxiety and Depression Scale (HADS; Zigmond 
& Snaith, 1983) was used to screen for depression in patients with operable breast cancer within 
one year of cancer diagnosis and was a sensitive indicator of mood disorders in women under the 
age of 50 (Ramirez, Richards, Jarrett, & Fentiman, 1995). However, the majority of studies 
utilizing the HADS have revealed questionable psychometric properties including poor 
reliability, discriminant validity, predictive validity, and sensitivity toward identifying mood 
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disorders in breast cancer patients (Berard et al., 1998; Costantini et al., 1999; Hall, A’hern, & 
Fallowfield, 1999; Love, Grabsch, Clark, Bloch, Kissane, 2004; Love, Kissane, Bloch, & Clark, 
2002; Ramirez et al., 1995). In one large study that included breast cancer patients from 
outpatient oncology clinics (Berard, Boermeester, & Viljoen, 1998), the HADS and Beck 
Depression Inventory (BDI: Beck, Ward, Mendelson, Mock, & Erbaugh, 1968) were used to 
screen for depression. Approximately 22% of participants also completed a structured diagnostic 
interview and the overall prevalence of MDD was estimated at 14%. Results indicated the HADS 
depression subscale and BDI collectively allowed for maximum sensitivity with optimal cut-
points specified (HADS: 8; BDI: 16). Another study of head and neck cancer patients examined 
the sensitivity, specificity, and positive predictive values of the BDI-II, CES-D, HADS, and 
HRSD in screening for MDD (Katz, Kopek, Waldron, Devins, & Tomlinson, 2004). The 
prevalence of MDD was 20% and all measures had strong convergent and predictive validity.  
A study including a sample of newly diagnosed patients with various cancer types used 
the CES-D to assess depression prevalence, indicating the CES-D had strong internal consistency 
(α = .87) and a depression prevalence rate of 40% based on a cut-point of 16 (Beeber, Shea, & 
McCorkle, 1998). Pasacreta (1997) used the Diagnostic Interview Schedule (DIS; Robins, 
Helzer, Croughnan, Williams, & Spitzer, 1987) and CES-D with women less then seven months 
following their breast cancer diagnosis and reported 9% met criteria for MDD and 24% showed 
elevated depressive symptoms. Pasacreta (1997) concluded the CES-D had limited predictive 
power, however a more recent study demonstrated the CES-D (as well as BDI-II and HRSD) had 
strong internal consistency and high sensitivity and specificity in distinguishing depressed and 
non-depressed patients with various cancer types (Hopko et al., 2007). Finally, there are very 
limited data suggesting the Patient Health Questionnaire-9 depression module (PHQ-9; Spitzer, 
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Kroenke, &Willams, 1999) distress and impact thermometers (Akizuki, Yamawaki, Akechi, 
Nakano, & Uchitomi, 2005; Holland, 1999), and other abbreviated assessment methods may be 
reliable and valid measures of depression in medical samples including individuals with breast 
cancer (Gil, Grassi, Travado, Tomamichel, & Gonzalez, 2005; Mitchell, 2007; Hegel et al., 
2008; Kroenke, Spitzer, & Williams, 2001). 
  The BDI-II, CES-D, and HRSD are three of the most widely used depression measures 
and there are many significant reasons for investigating their psychometric properties. These 
reasons include the need to examine construct validity through comparing depression symptom 
factors across different depression measures, determining the equivalence of factor structures 
across samples or groups (e.g., gender, ethnicity, age, or medical diagnoses), assessing 
differential depression severity across patient samples, determining whether specific depression 
symptom factors within a measure correlate differentially with external variables, and evaluating 
the practicality and empirical value of using these depression measures in the assessment and 
intervention process among patients with varying demographic, psychological, and medical 
characteristics (Shafer, 2006). Accordingly, in the context of a paucity of research exploring 
psychometric properties of depression measures in breast cancer patients with MDD and 
considering how frequently these instruments are used with this population, systematic 
evaluation of factor structures, internal consistency, and convergent and discriminant validity of 
depression measures has major theoretical and clinical implications. Considering the prevalence 
and impact of depression in breast cancer patients, examining psychometric properties of 
potentially valuable depression screening measures is a pressing need.  
 This study investigated the properties of three depression measures in a sample of breast 
cancer patients with MDD as diagnosed via structured clinical interviews. Primary hypotheses 
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were as follows: (a) descriptive data would reveal normatively distributed data (i.e., skewness 
and kurtosis); (b) descriptive data would resemble that reported in other clinical samples of 
MDD patients and exceed that of non-clinical samples; (c) the BDI-II, CES-D, and HRSD would 
be associated with high internal consistency; (d) strong convergent validity would be 
demonstrated via high correlations across depression measures and MDD severity as assessed 
through structured diagnostic interviews; and (e) discriminant validity would be demonstrated 
with relatively lower correlations with a commonly used measure of anxiety (i.e., Beck Anxiety 
Inventory: Beck & Steer, 1993). Finally, as this was the pioneering study of factor structures of 
these measures in breast cancer patients with MDD, both confirmatory and exploratory factor 
analyses were conducted to examine similarities to existing structural models. 
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Chapter 2 
Method 
 
Participants 
Participants included 127 female breast cancer patients recruited at the University of 
Tennessee Medical Center Cancer Institute. Participants were included from treatment outcome 
studies examining the efficacy of behavioral activation treatments for breast cancer patients with 
MDD (Hopko et al., 2005, 2008, 2011) and were recruited by advanced clinical psychology 
doctoral students or referred by treating oncologists. The principal investigator of the three 
studies (DH) supervised all doctoral students. Participants were eligible if they were above 18 
years of age, had been diagnosed with breast cancer, and had a principal (and primary) diagnosis 
of MDD of moderate severity [i.e., at least “4” on a 0 (no depressive symptoms) to 8 (very 
severe symptoms) scale]. Depending on the study, MDD was diagnosed using either the 
Structured Clinical Interview for DSM-IV (SCID-I; First, Spitzer, Gibbon, & Williams, 1996) or 
the Anxiety Disorders Interview Schedule-IV (ADIS-IV; Brown, DiNardo, & Barlow, 1994).  
Participants ranged in age from 38 to 78 years [M = 54.9 years (SD = 11.7)]. The 
majority of participants were Caucasian (95.3%; 4.7% African American). Marital status was as 
follows: Married (56.7%), Single (25.2%), Divorced (15%), and Separated (3.1%). The 
participants averaged 14.4 years of education (SD = 2.7). Approximately 42% of the sample was 
employed either full or part-time, and remaining patients were unemployed (28%) or retired 
(30%). Cancer data were gathered from pathology reports at the University of Tennessee 
Medical Center’s Cancer Institute. The average length of time since cancer diagnosis was 2.8 
years (SD = 3.8), and 78.7% of patients had infiltrating ductal carcinoma (IDC), 11% ductal 
carcinoma in situ (DCIS), and 10.3% lobular carcinoma in situ (LCIS). The sample included 
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patients of all cancer stages (Stage 0: 22%; Stage 1: 33.9%; Stage 2; 30.7%; Stage 3; 11.8%; 
Stage 4; 1.6%). A total of 75% tested positive for estrogen receptor status, 65% for positive 
progesterone receptor status, and 16% for the HER-2/NEU gene. In terms of cancer treatment, 
94% of patients had surgery (i.e., lumpectomy, mastectomy), 74% had chemotherapy, 60% had 
radiation treatment, and 1% had hormonal therapy. Participants were included if not taking 
antidepressant or anti-anxiety medication (48%), or if they were taking such medications, had 
been stabilized at a consistent dosage for 8 weeks prior to study assessment (48%). Due to 
ethical considerations with regard to withholding treatment, patients also were included who had 
initiated taking medication but were not stabilized (4%). A total of 10% reported having been 
hospitalized for depression and 3% for another psychiatric problem. Mean level of ADIS-IV or 
SCID-I clinician-rated severity of MDD was 5.3 (SD = 1.1), suggesting moderate clinical 
depression. Coexistent diagnoses included GAD (n = 39; 30.7%), PTSD (n = 6; 4.7%), Social 
Phobia (n = 12; 9.3%), Panic Disorder (n = 4; 3.1%), Anxiety NOS (n = 4; 3.1%), Specific 
Phobia (n = 3; 2.4%), Dysthymia (n = 2; 1.6%), and OCD (n = 1; 0.8%).  
Assessment Measures  
 The Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV; Brown et al., 1994) is 
a semi-structured interview used as a diagnostic assessment for anxiety, mood, somatoform, 
substance abuse and psychotic disorders. Disorders are separated into distinct modules and 
symptoms are rated on a nominal scale and given ratings based on a continuum of severity and 
interference. The ADIS-IV has excellent reliability and validity (Brown, DiNardo, Lehman, & 
Campbell, 2001).  
 The Structured Clinical Interview for DSM-IV (SCID-I; First, Spitzer, Gibbon, & 
Williams, 1996) is a semi-structured interview used to diagnose Axis I disorders based on DSM-
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IV criteria. The SCID is separated into modules according to diagnosis. Symptoms for each 
diagnosis are categorized as present, sub-threshold, or absent. The inter-rater reliability of the 
SCID-I ranges from good to excellent depending on the sample and diagnostic module 
(Lobbestael, Leurgans, & Arntz, 2011; Löwe et al., 2004). 
The Beck Depression Inventory-II (BDI-II; Beck et al. 1996) consists of 21 items rated on 
a 4-point Likert scale. The instrument has excellent reliability and validity data with depressed 
younger and older adults (Beck et al., 1996; Dozois, Dobson, & Ahnberg, 1998; Nezu, Ronan, 
Meadows, & McClure, 2001). The psychometric properties of the BDI-II have been studied in 
cancer patients and a diverse primary care sample, with the instrument having strong predictive 
validity as it pertains to a diagnosis of MDD, strong internal consistency (α = .94), and adequate 
item-total correlations (Arnau, Meagher, Norris, & Bramson; 2001; Hopko et al., 2007; Katz, 
Kopek, Waldron, Devins, & Thomlinson, 2004). 
 The Center for Epidemiologic Studies Depression Scale (CES-D: Radloff, 1977) contains 
20 items selected from previously validated scales of depression. It includes six components: 
depressed mood; feelings of guilt and worthlessness; feelings of helplessness and hopelessness; 
psychomotor retardation; loss of appetite; and sleep disturbance. Reliability and validity of the 
CES-D have been tested in general and clinical populations, yielding very good internal 
consistency [α = .85 for the general population and 0.90 for a psychiatric population]. 
Satisfactory test-retest reliability over a 2- to 8-week period ranged from 0.51 to 0.67 and from 
0.32 to 0.54 over a 3- to 12-month period. The CES-D has moderate convergent validity with the 
HRSD (r = 0.65) (Craig, Richardson, Pass, & Bregman, 1985).  
 The Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960) is a 17-item semi-
structured interview designed to measure symptom severity in depressed patients. The instrument 
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is the most widely used outcome measure for evaluating depression and is a standard outcome 
measure in clinical trials (Kobak & Reynolds, 1999; Wolf & Hopko, 2008). 
The Beck Anxiety Inventory (BAI; Beck, Epstein, Brown, & Steer, 1988) is a 21-item 
measure designed to distinguish cognitive and somatic symptoms of anxiety from those of 
depression. Good psychometric properties have been demonstrated among community, medical, 
and psychiatric outpatient samples (Antony, Orsillo, & Roemer, 2001; Morin et al., 1999; 
Wetherell & Areán, 1997).  
Procedure 
All participants were administered either the SCID or ADIS-IV by an advanced clinical 
psychology doctoral student trained by the principal investigator (DH). Those patients who were 
diagnosed with MDD then completed the BDI-II, BAI, CES-D, and HRSD. The original studies 
(Hopko et al., 2005, 2008, 2011) included several assessment intervals (i.e., pre-treatment, post-
treatment, 3-month, 6-month, 9-month, and 12-month follow-ups). All data used for the 
following analyses were from the pre-treatment assessments of all patients. All assessments were 
completed at the University of Tennessee Medical Center Cancer Institute. 
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Chapter 3 
Results 
Descriptive Data and Internal Consistency 
Tests of multivariate normality were used to examine distributional characteristics of data 
for each depression measure (n = 127). For the BDI-II (M = 26.32, SD = 10.27: α = .90), both the 
symmetry (skewness = .72, SE = .22) and “flatness” (kurtosis = .33, SE = .43) of the distribution 
were within acceptable limits (Hair et al., 1995). In addition, a powerful test of normality for 
sample sizes over 100 (Razali & Wah, 2007), the Kolmogorov-Smirnov (KS) statistic suggested 
sample data were normally distributed (KS = .08, p = .06). Significantly increased depression 
was observed relative to a large non-clinical sample [(M = 8.36, SD = 7.16); t (152) = 18.77, p < 
.01; Whisman, Perez, & Ramel, 2000]. The BDI-II scores did not significantly differ from a 
sample of clinically depressed outpatients [(M = 28.64, SD = 11.75); t (293) = -1.90, p = .06; 
Steer, Ball, Ranieri, & Beck, 1999], but was significantly lower than a recent treatment-seeking 
sample of depressed patients [(M = 32.0, SD = 7.5); t (198) = -5.52, p < .01; Dimidjian et al., 
2006]. The current sample of depressed breast cancer patients did report significantly greater 
depression relative to three groups of cancer patients including patients receiving antineoplastic 
and supportive treatments [(M = 15.47, SD = 8.36); t (151) = 7.83, p < .01; O’Mahony et al., 
2005], women receiving chemotherapy for early stage breast cancer [(M = 11.10, SD = 6.55); t 
(139) = 11.71, p < .01; Bower et al., 2011], and breast cancer patients following treatment (i.e., 
chemotherapy, radiation, surgery) [(M = 7.34, SD = 7.58); t (130) = 13.72, p < .01; Bower et al., 
2011]. For this study sample, internal consistency of the BDI-II was strong (α = .90).  
For the CES-D (M = 30.56, SD = 10.05: α = .85), both the skewness (-.12, SE = .22) and 
kurtosis (-.49, SE = .43) were within acceptable limits and data were normally distributed (KS = 
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.06, p = .20). Internal consistency of the CES-D was strong (α = .85). Significantly greater 
depression was reported on the CES-D in this sample relative to a large non-clinical community 
sample [(M = 5.02, SD = 7.23); t (161) = 26.86, p < .01; Boyd, Weissman, Thompson, & Myers, 
1982], a sample of depressed cancer patients [(M = 23.6, SD = 7.02); t (120) = 5.16, p < .01; 
Bodurka-Bevers et al., 2000], and several medical samples including a non-cancerous medical 
group [(M = 8.3, SD = 6.4); t (185) = 22.59, p < .01; Van Wilgen, Dijkstra, Stewart, Ranchor, & 
Roodenburg, 2006], and two samples of breast cancer patients [(M = 10.5, SD = 8.3); t (234) = 
18.63, p < .01; Van Wilgen et al., 2006]; [(M = 11.53, SD = 9.01); t (221) = 14.77, p < .01; 
Antoni et al., 2001].  
Finally, for the HRSD (M = 14.31, SD = 6.11: α = .75), sample data also were normally 
distributed [skewness (.35, SE = .22); kurtosis (-.40, SE = .43); KS = .07, p = .20]. Internal 
consistency of the HRSD for the current sample was acceptable (α = .75). Because the HRSD is 
a clinician-rated measure for individuals with MDD, there were no non-clinical samples to 
compare to the present sample. Clinician-rated depression on the HRSD was significantly lower 
than two large sample of depressed patients [(M = 20.7, SD = 4.2); t (187) = -10.65, p < .01; 
Dimidjian et al., 2006] [(M = 19.5, SD = 4.4); t (197) = -8.48, p < .01; Elkin et al., 1989] but was 
comparable to heterogeneous samples of patients with cancer across many sites and stages 
[Sample 1: (M = 16.02, SD = 7.28); t (88) = -1.53, p = .13; Sample 2: (M = 14.31, SD = 8.12); t 
(91) = -0.06, p = .95; Foley, Baillie, Huxter, Price, & Sinclair, 2010]. 
Convergent and Discriminant Validity 
Convergent validity was assessed based on Pearson Product-Moment correlations among 
depression measures and MDD depression severity as measured by a structured clinical 
interview. As presented in Table 1, strong convergent validity was evident between the BDI-II 
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and CES-D. Convergent validity was more moderate between the HRSD and both the BDI-II and 
CES-D. All three measures exhibited moderate convergent validity with depression severity as 
assessed via structured diagnostic interviews. Discriminant validity was examined through 
correlations between depression measures and the BAI. Based on a series of non-significant 
Pearson’s tests of dependent correlations, there was minimal evidence to support discriminative 
validity in terms of the BAI correlating significantly less with depression measures relative to the 
inter-correlations among depression measures. In fact, only the relationship of the BDI-II and 
CES-D (r = .72) compared to the BDI-II and BAI (r = .63) approached statistical significance (z 
=1.60, p = .06).  
Confirmatory Factor Analyses 
 
Confirmatory factor analyses (CFA) were used to examine the adequacy of existing 
structural models for the BDI-II, CES-D, and HRSD as applied to data obtained from the current 
sample of female breast cancer patients diagnosed with MDD. All statistics were computed using 
SPSS Amos for structural equation modeling (Arbuckle, 2006). As per recommendations in 
reporting results of CFA (Thompson & Daniel, 1996), the Root Mean Square Error of 
Approximation (RMSEA), chi-square, and the Bentler’s comparative (BCFI), goodness-of-fit 
(GFI), adjusted goodness of fit (AGFI), and normed fit (NFI) indexes are presented. 
Contemporary goodness-of-fit criteria were used whereby an RMSEA of .06 and a CFI (and 
GFI) value of .95 were required for conclusions to be drawn that a good fit existed between the 
hypothesized model and observed data (Browne & Cudeck, 1992; Hu & Bentler, 1998). The χ2/ 
df values were expected to be as low as 2 and as high as 5 to indicate a value within the range of 
reasonable fit (Marsh & Hocevar, 1985).  
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Hypothesized Models  
As outlined in the introduction, the BDI-II was assessed using both two- and three-factor 
models, as well as one hierarchical four-factor measurement model. The two-factor models 
included somatic-affective and cognitive subscales (Steer et al., 1998; Arnau et al., 2001; Huang 
& Chen, 2014). The two three-factor models included somatic, affective, and cognitive factors 
(Seignourel, Green, & Schmitz, 2008; Vanheule, Desmet, Groenvynck, Rosseel, & Fontaine, 
2008). The hierarchical four-factor measurement model was made of three first-order factors 
(negative attitude, performance difficulty, somatic elements) and one second order factor 
(depression) (Whisman, Judd, Whiteford, & Gelhorn, 2013). 
The CES-D was compared to a both three and four-factor models. The three-factor model 
consisted of negative affect, anhedonia, and somatic symptoms subscales (Carleton et al., 2013). 
The four-factor model included somatic, depressed affect, positive affect, and interpersonal 
problems subscales (Shafer, 2006). Finally, the HRSD was examined using a one-factor model 
(depression; Bech, Fava, Trivedi, Wisniewski, & Rush, 2011) and several four-factor models. 
One model consisted of a somatic anxiety/somatization, psychic anxiety, pure depression, and 
anorexia subscales (Pancheri, Picardi, Pasquini, Gaetano, & Biondi, 2002). The original 
Hamilton (1960) article and subsequent study (1967) both discuss four-factor models, but all of 
the subscales are not clearly labeled. Some factor labels from those models include retarded 
depression, agitated depression, anxiety reaction, general depression, and retarded vs. agitated 
depression. The final model examined consisted of anxiety, depression, insomnia, and somatic 
subscales and was the closet to being considered an appropriate fit with this sample’s data 
(Shafer, 2006). As highlighted in Table 2, data from the current patient sample generally was a 
poor fit with previously established factor structures for all three depression measures.  
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Exploratory Factor Analyses 
Following the CFA findings, exploratory factor analyses (EFA) were performed on the 
BDI-II, CES-D, and HRSD to investigate alternative factor structures. For each EFA, a principal 
components extraction and varimax rotation method was used with the number of factors 
initially unspecified. An orthogonal varimax rotation was chosen to allow for clarification of 
uncorrelated factors within each measure. The factor loadings and related interpretability (i.e., 
face validity of items), scree-plot analysis (Cattell, 1966), and factor eigenvalues as assessed 
using parallel analysis procedures (Glorfeld, 1995; Watkins, 2000) were employed to determine 
optimal factor structure of the three depression measures.   
BDI-II. An EFA was first performed on the BDI-II items with the number of factors 
unspecified for the model. Factor eigenvalues were then assessed using parallel analysis. A two-
factor model was found to be most parsimonious for the data. A second EFA was then performed 
specifying a two-factor model. The two factors accounted for 43% of the variance in 
participants’ responses (Factor 1 = 34%, eigenvalue = 7.17; Factor 2 = 9%, eigenvalue = 1.81). 
The two-factor solution is presented in Table 3. To load significantly on a factor, an item had to 
have a factor loading greater then or equal to .40, with the loading on the alternative factor(s) 
being greater then or equal to a .20 difference from the primary factor (Hair, Anderson, Tatham, 
& Black, 1995). Given the nature of the nine items loading onto factor 1, it was labeled Negative 
Attitudes Toward Self, while the nine items loading onto factor 2 were labeled Somatic-
Affective. The agitation, indecisiveness, and concentration difficulty items did not load 
significantly or discriminantly onto either of the two factors.  
CES-D. An initial EFA with the number of factors unspecified was performed on the 
CES-D. Following examination of results of the first EFA and using parallel analysis procedures 
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to determine optimal factor structure, the second EFA was performed with three factors 
specified. The three factors accounted for 49% of the variance in participants’ responses (Factor 
1 = 28%, eigenvalue = 5.56; Factor 2 = 12%, eigenvalue = 2.39; Factor 3 = 9%, eigenvalue = 
1.70). The three-factor solution is displayed in Table 4. Items were designated as significant 
loadings based on the algorithm described above. The items loading significantly onto factor 1 
were almost identical to two of Radloff’s (1977) original factors, the Somatic and Retarded 
Activity factor and Depressed Affect factor. Factor 1 was labeled Somatic-Depressed Affect. The 
items that loaded onto factor 2 were three of the four items included in Radloff’s Positive Affect 
factor, and therefore factor 2 was given the same label. Finally, factor 3 consisted of both items 
in Radloff’s original Interpersonal Problems factor, and two additional items. Because the 
additional two items, “I felt that I was just as good as other people” and “I thought my life had 
been a failure,” could be interpreted as interpersonal comparisons, factor 3 was labeled 
Interpersonal. On the CES-D, only items 7 and 20 did not load significantly on any of the three 
factors.  
HRSD. As with the two self-report measures, results from an initial EFA with unspecified 
factors and parallel analyses indicated a three-factor model was most parsimonious with data 
obtained on the HRSD. A second EFA was then performed specifying three factors. The three 
factors accounted for 40% of the variance (Factor 1 = 22%, eigenvalue = 3.73; Factor 2 = 9%, 
eigenvalue = 1.61; Factor 3 = 9%, eigenvalue = 1.47). The three-factor solution is presented in 
Table 5. Using the item designation procedure highlighted above, unlike the BDI-II and CES-D, 
which more concisely mapped onto empirically derived factor structures, the HRSD factors were 
not as clearly defined. Due to the nature of the six items loading significantly onto factor 1, it 
was labeled Somatic Anxiety. The five items loading onto factor 2 were all symptoms of 
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depression, so factor 2 was labeled Depressive Affect. Three of the four items loading onto 
factor 3 were insomnia and the fourth assessed weight loss, resulting in this factor being labeled 
Neurovegetative. Although somewhat less clearly defined than the BDI-II and CES-D factors, 
HRSD factors reveal high face and content validity with the construct of depression.  
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Chapter 4 
Discussion  
The primary aim of this study was to investigate the psychometric properties and factor 
structures of three common measures of depression to evaluate their appropriateness for use with 
depressed breast cancer patients. Following tests of data normality, internal consistency as well 
as convergent and discriminant validity of the three measures were assessed. Confirmatory factor 
analyses investigated the fit of sample data with several existing factor structures for each 
depression measure and exploratory factor analyses provided additional information about the 
underlying factor structure of the data. For all three depression measures, tests of multivariate 
normality revealed that distribution scores were within acceptable limits, indicating sample data 
were normally distributed. Internal consistency of both the BDI-II and CES-D were strong, with 
the HRSD having lower but adequate internal consistency. Good convergent validity also was 
evident in the relationships of all three depression measures as well as their associations with 
severity of MDD as assessed by structured diagnostic interviews. It is conceivable that the more 
moderate convergent validity between the BDI-II and the HRSD was an administration artifact 
(i.e., self-report versus clinician-rated). Discriminant validity with a measure of somatic anxiety 
(BAI) was not demonstrated, suggesting that for depressed breast cancer patients it might be 
difficult to discriminate between symptoms of depression, anxiety, and somatic complaints 
potentially related to the diagnosis and treatment of breast cancer (Raison & Miller, 2003).  
Pertaining to cross-sample descriptive comparisons, self-reported depression on the BDI-
II was significantly higher than a non-clinical sample as well as referenced samples of cancer 
patients, and the data were equivocal in terms of comparisons with clinically depressed patients. 
Similar to the BDI-II, self-reported depression on the CES-D was significantly higher than a 
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non-clinical community sample. Relative to clinically depressed samples, CES-D rated 
depression was lower in the current sample but higher when compared to several medical 
samples that included depressed cancer patients. Clinician-rated depression on the HRSD was 
significantly lower relative to clinically depressed samples, but largely consistent with studies of 
cancer patients at different stages in cancer treatment, and regardless of whether cancer patients 
were seeking treatment for depression. Collectively, these findings indicate breast cancer patients 
with depression report significant psychological distress on common measures of depression. 
For all three depression measures, confirmatory factor analyses of existing factor 
structures did not fit well with current data. For the BDI-II, the closest fit to this sample was a 
three-factor model including somatic, affective, and cognitive subscales (Vanheule, Desmet, 
Groenvynck, Rosseel, & Fontaine, 2008). Nonetheless, even this model was rejected as all fit 
indices were all outside acceptable ranges. A subsequent exploratory factor analyses revealed 
that the BDI-II consisted of two-factors, labeled “Negative Attitudes Toward Self” and 
“Somatic-Affective.” The “Somatic-Affective” factor is common among two-factor models 
(Steer et al., 1998; Arnau et al., 2001; Huang & Chen, 2014) but the “Negative Attitudes 
Towards Self” is not generally evident in two-factor structures. The “Negative Attitudes 
Towards Self” factor does overlap with the “Negative Attitude” first-order factor in a recent 
hierarchical model, however (Whisman, Judd, Whiteford, & Gelhorn, 2013), and is similar to the 
“Negative Attitudes Towards Self” factor observed in the original BDI (Beck & Lester, 1973).  
Sample data on the CES-D were subjected to both a three- and four-factor model of the 
CES-D using confirmatory factor analyses, with the former model providing the closest fit, albeit 
still unsatisfactory based on not meeting fit index criteria. A subsequent exploratory factor 
analyses revealed a three-factor model consisting of “Somatic-Depressed Affect,” “Positive 
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Affect,” and “Interpersonal” factors. Similar to self-report measures, confirmatory factor 
analyses of the HRSD revealed inadequate fit for the one-factor model as well as several four-
factor models. Exploratory factor analyses revealed an underlying three-factor structure of the 
HRSD, including “Somatic Anxiety, “Depressive Affect,” and “Neurovegetative” factors.  
 The present study yielded provocative findings in terms of the utility of three common 
measures to assess depression in breast cancer patients. A few notable limitations include using a 
reasonably large sample size, however, a larger sample size from several different recruitment 
sites would strengthen study findings. Second, this sample consisted mainly of Caucasian 
females, and although this demographic feature is representative of the area in which data were 
collected, it reduces the generalizability of the results to other racial and ethnic groups. Third, the 
majority of the sample was composed of patients diagnosed with Stage 0-2 breast cancer, with 
only 13% of the sample diagnosed with Stage 3 or 4 breast cancer. Although it is understandable 
that patients with more severe cancer and (possibly) more invasive cancer treatment would be 
less likely to have the energy and motivation to participate in treatment outcome studies, it will 
be important to address this issue in future research to better understand whether depression 
measures are appropriate for use with breast cancer patients in all stages of cancer. Finally, as the 
study sample included breast cancer patients from one medical center from largely rural areas, it 
will be important to assess the generalizability of results to other medical centers and 
geographical regions.  
Although the study has some noteworthy limitations, it provides an important preliminary 
investigation of three commonly used depression measures with a clinically depressed breast 
cancer sample. A psychometric examination of this kind has not been done with both a clinically 
depressed sample of breast cancer patients and thus adds to our knowledge of the appropriateness 
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of measures toward assessing depression and cancer patients and medical populations in general. 
Results of this study reveal several findings that support the notion that these measures are 
suitable for use in depressed breast cancer patients, including good distributional characteristics, 
adequate to strong internal consistency, and good convergent validity. However, further 
investigation of the discriminative validity of these measures is necessary to better determine 
construct validity relative to affective measures of anxiety. Given the medical sample studied, 
perhaps using less somatic measures of anxiety such as the State-Trait Anxiety Inventory or Penn 
State Worry Questionnaire might yield increased support for the discriminant validity of 
depression measures. Finally, it was evident that existing factor structures of depression 
measures were largely inadequate insofar as generalizing to this sample of cancer patients. 
Accordingly, interpretation of scores on these measures may be better accomplished via 
reference to more valid structural models obtained through exploratory factor analyses -- 
providing a more accurate conceptualization of the dimensions of MDD in breast cancer patients.  
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Table 1.  
Correlations Among Depression and Anxiety Measures 
 1 2 3 4 5 
1. BDI-II - .72 .58 .63 .60 
2. CES-D  - .58 .56 .58 
3. HRSD   - .56 .57 
4. BAI    - .35 
5. SCID/ADIS     - 
Note. All correlations are significant at the 0.001 level (2-tailed).  
BDI-II = Beck Depression Inventory-II; CES-D = Center for Epidemiologic Studies Depression 
Scale; HRSD = Hamilton Rating Scale for Depression; BAI = Beck Anxiety Inventory; 
SCID/ADIS = Severity rating from structured clinical interview (ADIS-IV or SCID-I). 
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Table 2. 
Confirmatory Factor Analyses of Established Models  
 Citation Factor 
Model 
Co-
variance 
of 
factors 
RMSEA BCFI GFI AGFI NFI χ2/ df 
 
p 
BDI-II Steer et al., 
1998 
2 Yes .08 .87 .84 .79 .75 1.76 .00 
BDI-II Arnau, 
Meagher, 
Norris, & 
Bramson,  
2001 
 
2 Yes .07 .85 .82 .78 .71 1.65 .00 
BDI-II Huang & 
Chen, 2014 
2 Yes .08 .84 .81 .76 .71 1.81 .00 
BDI-II Seignourel, 
Green, & 
Schmitz, 
2008 
3 Yes .08 .82 .80 .75 .69 1.86 .00 
BDI-II Vanheule, 
Desmet, 
Groenvync
k, Rosseel, 
& Fontaine, 
2008 
3 Yes .07 .89 .87 .83 .76 1.67 .00 
BDI-II Whisman, 
Judd, 
Whiteford, 
& Gelhorn, 
2013 
Hierar
-chical  
4 .08 .84 .81 .76 .71 1.75 .00 
CES-D Carleton et 
al., 2013 
3 Yes .07 .92 .87 .81 .81 1.59 .00 
CES-D Shafer, 
2006 
4 Yes .08 .81 .79 .73 .68 1.87 .00 
HRSD Bech, Fava, 
Trivedi, 
Wisniewski
, & Rush, 
2011 
1 No .08 .72 .84 .80 .53 1.72 .00 
HRSD Hamilton, 
1960 
4 No .10 .57 .80 .73 .44 2.13 .00 
HRSD Hamilton, 
1967 
4 No .09 .67 .89 .77 .54 1.99 .00 
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Table 2. Continued 
 Citation Factor 
Model 
Co-
variance 
of 
factors 
RMSEA 
 
BCFI GFI AGFI NFI χ2/ df 
 
p 
 
HRSD Pancheri, 
Picardi, 
Pasquini, 
Gaetano, & 
Biondi, 
2002 
4 Yes .07 .81 .88 .83 .62 1.53 .00 
HRSD Shafer, 
2006 
4 Yes .06 .85 .88 .83 .64 1.40 .00 
Note. BDI-II = Beck Depression Inventory-II; CES-D = Center for Epidemiologic Studies 
Depression Scale; HRSD = Hamilton Rating Scale for Depression; BAI = Beck Anxiety 
Inventory; RMSEA = Root Mean Square Error Approximation; CFI = Comparative Fit Index; 
GFI = Goodness-of-Fit Index; AGFI = Adjusted Goodness-of-Fit Index; NFI = Normed Fit 
Index; χ2  = Chi-square /df = Degrees of Freedom; p = p-value of χ2/ df.  
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Table 3. 
Varimax Rotated Factor Loadings of BDI-II Items 
 Factor Loading 
Item 1 2 
1. Sadness .36 .59 
2. Pessimism .52 .26 
3. Past Failure .78 .19 
4. Loss of Pleasure .27 .61 
5. Guilty Feelings .81 .09 
6. Punishment Feelings .62 .18 
7. Self-Dislike .62 .30 
8. Self-Criticalness .82 .19 
9. Suicidal Thought or Wishes .47 .19 
10. Crying .25 .46 
11. Agitation  .39*  .32* 
12. Loss of Interest .30 .59 
13. Indecisiveness  .44•   .48•  
14. Worthlessness .67 .18 
15. Loss of Energy .18 .71 
16. Changes in Sleep Pattern .23 .44 
17. Irritability .54 .21 
18. Changes in Appetite .08 .68 
19. Concentration Difficulty   .41•   .44• 
20. Tiredness or Fatigue .14 .73 
21. Loss of Interest in Sex .15* .37* 
Note. BDI-II = Beck Depression Inventory-II. Factor loadings in bold specify the designated 
factor. * = Undesignated item. • = Item loads on to more than one factor. Factor 1 = Negative 
Attitudes Toward Self. Factor 2 = Somatic-Affective. 
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Table 4. 
Varimax Rotated Factor Loadings of CES-D Items 
 Factor Loading 
Item 1 2 3 
1. Bothered by things .60 .14 .14 
2. Poor appetite .51 .18 .31 
3. Could not shake the blues .73 .32 .09 
4. Feel as good as others .04 .14 .61 
5. Couldn’t keep mind on tasks .55 .04 .01 
6. Felt depressed .66•  .41•  .15 
7. Everything an effort .56• .50• .04 
8. Hopeful about future .08 .70 .05 
9. Life is a failure .26 .25 .68 
10. Felt fearful .58 .13 .34 
11. Restless sleep .59 .11 .08 
12. Felt happy .01 .80 .21 
13. Talked less than usual .47 .04 .20 
14. Felt lonely .60 .03 .27 
15. People were unfriendly .10 .10 .59 
16. Enjoyed life .05 .78 .18 
17. Crying spells .48 .17 .28 
18. Felt sad .68 .24 .23 
19. People dislike me .25 .01 .78 
20. Could not get going   .56•  .46•  .13 
Note. CES-D = Center for Epidemiologic Studies Depression Inventory Scale. Factor loadings in 
bold specify the designated factor. • = Item loads on to more than one factor. Factor 1 = 
Somatic-Depressed Affect. Factor 2 = Positive Affect. Factor 3 = Interpersonal. 
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Table 5. 
Varimax Rotated Factor Loadings of HRSD Items  
 Factor Loading 
Item 1 2 3 
1. Depressed mood .02 .66 .22 
2. Guilt .28 .50 .06 
3. Suicide .42 .05 .16 
4. Insomnia initial .03 .25 .46 
5. Insomnia middle  .12 .25 .61 
6. Insomnia delayed .27 .12 .68 
7. Work and interests .19 .50 .30 
8. Retardation .20 .42 .18 
9. Agitation .12   .39*   .38* 
10. Anxiety psychic   .53•    .53•  .04 
11. Anxiety somatic .70 .26 .02 
12. Gastrointestinal .59 .13 .38 
13. General somatic .71 .26 .01 
14. Libido loss .68 .20 .06 
15. Hypochondriasis .44 .24 .15 
16. Weight loss .14 .14 .63 
17. Insight loss .01 .40 .13 
Note. HRSD = Hamilton Rating Scale for Depression. Factor loadings in bold specify the 
designated factor. * = Undesignated item. • = Item loads on to more than one factor. Factor 1 = 
Somatic Anxiety. Factor 2 = Depressive Affect. Factor 3 = Neurovegetative.  
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